Loading
RK-33 is an experimental drug from NATSAR Pharmaceuticals that blocks the DDX3 protein in cancer cells. It has been studied in the laboratory and a first trial in people is planned.
RK-33 is NATSAR Pharmaceuticals' DDX3 inhibitor. The company reports activity across 70 human cancer cell lines, with independent NCI testing, and in animal models alone and with radiation, and plans a phase 1A study of safety and maximum tolerated dose with an intravenous formulation. A National Cancer Institute SBIR award funds its development for breast cancer. No registered trial was found.
Binds the RNA helicase DDX3 and impedes its function, which NATSAR Pharmaceuticals reports activates cell death, inhibits Wnt signalling and blocks non-homologous end-joining DNA repair, making cells more sensitive to radiation. Connects to DDX3X.
1.RK-33 slips into a pocket on DDX3X.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"RK-33" OR ABSTRACT:"RK-33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RK-33, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/